Delpha Capital Management’s West Pharmaceutical WST Stock Holding History

Delpha Capital Management’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-288	Closed	-$28K	–	1230
2017 Q4	$28K	Buy	+288	New	+$28.2K	0.03%	608

Other funds holding WST

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Delpha Capital Management's WST Position: Q1 2018 in Review

Delpha Capital Management sold out of West Pharmaceutical (WST) in Q1 2018, closing a stake of 288 shares — an estimated $28K sold.

Delpha Capital Management first reported a position in WST in Q4 2017 and held it in 1 quarter. The position peaked at $28K in Q4 2017. 323 funds tracked by Wall St. Rank hold WST as of Q1 2018.

Delpha Capital Management reported no remaining West Pharmaceutical position as of Q1 2018 after selling out during the quarter.
Delpha Capital Management sold 288 West Pharmaceutical shares in Q1 2018, an estimated $28K.
Delpha Capital Management first reported a position in West Pharmaceutical in Q4 2017 and held it in 1 quarter.
Delpha Capital Management's West Pharmaceutical position peaked at $28K in Q4 2017.
323 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.